This ETF offers much more of a mid-cap tilt than other healthcare ETFs. As such, it provides purer U.S. healthcare exposure than do some of its peers, whose holdings include large-cap pharmaceutical companies with meaningful overseas businesses.
Morningstar's equity analysts expect healthcare spending in China to grow meaningfully during the next five to 10 years as China ages and becomes richer.
Utilization rates have turned a corner and are rising slightly. Read more